All Stories

  1. Recent trend in medical imaging modalities and their applications in disease diagnosis: a review

    Article • Multimedia Tools and Applications, October 2023, Springer Science + Business Media

    Pr Alexandre E Escargueil

  2. Shikonin, an inhibitor of inflammasomes, inhibits Epstein-Barr virus reactivation

    Article • Antiviral Research, September 2023, Elsevier

    Pr Alexandre E Escargueil

  3. Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells

    Article • Oncotarget, June 2023, Impact Journals, LLC

    Pr Alexandre E Escargueil

  4. Azaphilones Pigments from the Fungus Penicillium hirayamae

    Article • Colorants, January 2023, MDPI AG

    Pr Alexandre E Escargueil

  5. The C-Terminal Acidic Tail Modulates the Anticancer Properties of HMGB1

    Article • International Journal of Molecular Sciences, July 2022, MDPI AG

    Pr Alexandre E Escargueil

  6. Expression Pattern of Purinergic Signaling Components in Colorectal Cancer Cells and Differential Cellular Outcomes Induced by Extracellular ATP and Adenosine

    Article • International Journal of Molecular Sciences, October 2021, MDPI AG

    Pr Alexandre E Escargueil

  7. Distinction between 2′- and 3′-Phosphate Isomers of a Fluorescent NADPH Analogue Led to Strong Inhibition of Cancer Cells Migration

    Article • Antioxidants, May 2021, MDPI AG

    Pr Alexandre E Escargueil

  8. Colorectal Cancer and Immunity: From the Wet Lab to Individuals

    Article • Cancers, April 2021, MDPI AG

    Pr Alexandre E Escargueil

  9. Cytotoxic constituents from the wheat plant pathogen Parastagonospora nodorum SN15

    Article • Natural Product Research, February 2021, Taylor & Francis

    Dr Amr El-Demerdash, Pr Alexandre E Escargueil

  10. Secondary Metabolites from the Culture of the Marine-derived Fungus Paradendryphiella salina PC 362H and Evaluation of the Anticancer Activity of Its Metabolite Hyalodendrin

    Article • Marine Drugs, April 2020, MDPI AG

    Pr Alexandre E Escargueil

  11. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation

    Article • Antiviral Research, December 2019, Elsevier

    Pr Alexandre E Escargueil

  12. Epstein–Barr Virus BALF0 and BALF1 Modulate Autophagy

    Article • Viruses, November 2019, MDPI AG

    Pr Alexandre E Escargueil

  13. Detection of IgG directed against a recombinant form of Epstein-Barr virus BALF0/1 protein in patients with nasopharyngeal carcinoma

    Article • Protein Expression and Purification, October 2019, Elsevier

    Pr Alexandre E Escargueil

  14. Perspective: plasticity, the enemy of the good

    Article • Cancer Drug Resistance, January 2019, OAE Publishing

    Pr Alexandre E Escargueil

  15. Multifaceted Study on a Cytochalasin Scaffold: Lessons on Reactivity, Multidentate Catalysis, and Anticancer Properties

    Article • Chemistry - A European Journal, October 2018, Wiley

    Gilles Frison, Pr Alexandre E Escargueil

  16. Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

    Article • Clinical Cancer Research, May 2018, American Association for Cancer Research (AACR)

    Pr Alexandre E Escargueil

  17. Intramolecular Aryne-Furan Cycloadditions for the Synthesis of Anticancer Naphthalimides

    Article • The Journal of Organic Chemistry, March 2018, American Chemical Society (ACS)

    Pr Alexandre E Escargueil

  18. Quorum Sensing and Quorum Quenching in the Mediterranean Seagrass Posidonia oceanica Microbiota

    Article • Frontiers in Marine Science, July 2017, Frontiers

    Pr Alexandre E Escargueil

  19. Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology

    Article • Current Pharmaceutical Design, January 2017, Bentham Science Publishers

    Pr Alexandre E Escargueil

  20. Antimicrobial Oligophenalenone Dimers from the Soil Fungus Talaromyces stipitatus

    Article • Journal of Natural Products, December 2016, American Chemical Society (ACS)

    Pr Alexandre E Escargueil

  21. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair

    Article • Oncotarget, March 2016, Impact Journals, LLC

    Pr Alexandre E Escargueil

  22. Emergence of cytotoxic resistance in cancer cell populations: Single-cell mechanisms and population-level consequences

    Article • January 2016, American Institute of Physics

    Pr Alexandre E Escargueil

  23. Phenotype heterogeneity in cancer cell populations

    Article • January 2016, American Institute of Physics

    Pr Alexandre E Escargueil

  24. Talaroketals A and B, unusual bis(oxaphenalenone) spiro and fused ketals from the soil fungus Talaromyces stipitatus ATCC 10500

    Article • Organic & Biomolecular Chemistry, January 2016, Royal Society of Chemistry

    Pr Alexandre E Escargueil

  25. Unexpected talaroenamine derivatives and an undescribed polyester from the fungus Talaromyces stipitatus ATCC10500

    Article • Phytochemistry, November 2015, Elsevier

    Pr Alexandre E Escargueil

  26. BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder

    Article • Cell Cycle, June 2015, Taylor & Francis

    Pr Alexandre E Escargueil

  27. Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation

    Article • Cancer Research, March 2015, American Association for Cancer Research (AACR)

    Pr Alexandre E Escargueil

  28. Emergence of cytotoxic resistance in cancer cell populations*

    Article • ITM Web of Conferences, January 2015, EDP Sciences

    Pr Alexandre E Escargueil

  29. Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors

    Article • Bulletin of Mathematical Biology, December 2014, Springer Science + Business Media

    Pr Alexandre E Escargueil

  30. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor

    Article • Oncotarget, January 2014, Impact Journals, LLC

    Pr Alexandre E Escargueil

  31. DNA alkylation damage and autophagy induction

    Article • Mutation Research/Reviews in Mutation Research, October 2013, Elsevier

    Dr. Lisiane Borges Meira, Pr Alexandre E Escargueil

  32. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status

    Article • International Journal of Oncology, March 2013, Spandidos Publications

    Pr Alexandre E Escargueil

  33. ATP-dependent chromatin remodeling and histone acetyltransferases in 5-FU cytotoxicity in Saccharomyces cerevisiae

    Article • Genetics and Molecular Research, January 2013, Genetics and Molecular Research

    Professor Diego Bonatto, Pr Alexandre E Escargueil

  34. Saccharomyces cerevisiae as a model system to study the response to anticancer agents

    Article • Cancer Chemotherapy and Pharmacology, August 2012, Springer Science + Business Media

    Professor Diego Bonatto, Pr Alexandre E Escargueil

  35. The DNA damage response to monofunctional anticancer DNA binders

    Article • Drug Discovery Today Disease Models, June 2012, Elsevier

    Pr Alexandre E Escargueil

  36. PARPs and the DNA damage response

    Article • Carcinogenesis, March 2012, Oxford University Press (OUP)

    Pr Alexandre E Escargueil

  37. EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

    Article • Clinical Cancer Research, October 2011, American Association for Cancer Research (AACR)

    Pr Alexandre E Escargueil

  38. Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

    Article • Molecular Cancer Therapeutics, August 2011, American Association for Cancer Research (AACR)

    Pr Alexandre E Escargueil

  39. Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906

    Article • Biochemical Journal, June 2011, Portland Press Ltd.

    Pr Alexandre E Escargueil

  40. The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: Implications for recognition and repair of antitumor alkylators

    Article • Biochemical Pharmacology, August 2010, Elsevier

    Pr Alexandre E Escargueil

  41. DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP

    Article • Biochemical Pharmacology, January 2010, Elsevier

    Pr Alexandre E Escargueil

  42. 5‐Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line

    Article • Journal of Applied Toxicology, December 2008, Wiley

    Pr Alexandre E Escargueil

  43. Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells

    Article • Journal of Cell Science, April 2008, The Company of Biologists

    Pr Alexandre E Escargueil

  44. What histone code for DNA repair?

    Article • Mutation Research/Reviews in Mutation Research, March 2008, Elsevier

    Pr Alexandre E Escargueil

  45. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743

    Article • Proceedings of the National Academy of Sciences, August 2007, Proceedings of the National Academy of Sciences

    Professor Diego Bonatto, Pr Alexandre E Escargueil

  46. Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIα is regulated directly by protein phosphatase 2A

    Article • Biochemical Journal, March 2007, Portland Press Ltd.

    Pr Alexandre E Escargueil

  47. P-glycoprotein and ‘lipid rafts’: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?)

    Article • Cellular and Molecular Life Sciences, April 2006, Springer Science + Business Media

    Pr Alexandre E Escargueil

  48. Down-Regulation of DNA Topoisomerase IIα Leads to Prolonged Cell Cycle Transit in G2 and Early M Phases and Increased Survival to Microtubule-Interacting Agents

    Article • Molecular Pharmacology, June 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Pr Alexandre E Escargueil

  49. Molecular cross-talk between the transcription, translation, and nonsense-mediated decay machineries

    Article • Journal of Cell Science, February 2004, The Company of Biologists

    Pr Alexandre E Escargueil

  50. Catalytic topoisomerase II inhibitors in cancer therapy

    Article • Pharmacology & Therapeutics, August 2003, Elsevier

    Pr Alexandre E Escargueil

  51. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane

    Article • Proceedings of the National Academy of Sciences, July 2002, Proceedings of the National Academy of Sciences

    Pr Alexandre E Escargueil

  52. Resistance mechanisms associated with altered intracellular distribution of anticancer agents

    Article • Pharmacology & Therapeutics, March 2000, Elsevier

    Pr Alexandre E Escargueil

  53. The catalytic activities of DNA topoisomerase II are most closely associated with the DNA cleavage/religation steps

    Article • Biochimie, July 1999, Elsevier

    Pr Alexandre E Escargueil